IBIO
iBio, Inc.
Price Chart
No historical data available
Latest Quote
$0.69
-0.02 (-3.18%)
Current Price
| Previous Close | $0.72 |
| Open | $0.73 |
| Day High | $0.73 |
| Day Low | $0.69 |
| Volume | 185,133 |
Stock Information
| Shares Outstanding | 64.31M |
| Total Debt | $2.20M |
| Cash Equivalents | $88.04M |
| Revenue | $100K |
| Net Income | $-33.04M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $45.66M |
| EPS (TTM) | $-0.32 |
| Exchange | NCM |
Recent Price History
No history data available. Data will be fetched automatically.
About iBio, Inc.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2Âexpressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on IBIO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $100,000 | $400,000 | $225,000 | $0 |
| Operating Revenue | $100,000 | $400,000 | $225,000 | $0 |
| Reconciled Cost Of Revenue | - | - | - | - |
| Cost Of Revenue | - | - | - | - |
| Expenses | ||||
| Interest Expense | $53,000 | $212,000 | $172,000 | $83,000 |
| Total Expenses | $30,238,000 | $19,002,000 | $16,859,000 | $29,343,000 |
| Other Income Expense | $-5,003,000 | - | $1,000,000 | $-98,000 |
| Net Non Operating Interest Income Expense | $2,097,000 | $225,000 | $191,000 | $130,000 |
| Interest Expense Non Operating | $53,000 | $212,000 | $172,000 | $83,000 |
| Operating Expense | $30,238,000 | $19,002,000 | $16,859,000 | $29,343,000 |
| General And Administrative Expense | $10,595,000 | $10,690,000 | $11,674,000 | $19,016,000 |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-33,044,000 | $-18,377,000 | $-15,443,000 | $-29,311,000 |
| Net Interest Income | $2,097,000 | $225,000 | $191,000 | $130,000 |
| Interest Income | $2,150,000 | $437,000 | $363,000 | $213,000 |
| Normalized Income | $-28,041,000 | $-18,377,000 | $-16,443,000 | $-29,213,000 |
| Net Income From Continuing And Discontinued Operation | $-33,044,000 | $-18,377,000 | $-24,907,000 | $-65,010,000 |
| Total Operating Income As Reported | $-35,141,000 | $-18,602,000 | $-16,634,000 | $-29,343,000 |
| Net Income Common Stockholders | $-33,044,000 | $-18,377,000 | $-24,907,000 | $-65,010,000 |
| Net Income | $-33,044,000 | $-18,377,000 | $-24,907,000 | $-65,010,000 |
| Net Income Including Noncontrolling Interests | $-33,044,000 | $-18,377,000 | $-24,907,000 | $-65,010,000 |
| Net Income Discontinuous Operations | $0 | $0 | $-9,464,000 | $-35,699,000 |
| Net Income Continuous Operations | $-33,044,000 | $-18,377,000 | $-15,443,000 | $-29,311,000 |
| Pretax Income | $-33,044,000 | $-18,377,000 | $-15,443,000 | $-29,311,000 |
| Special Income Charges | $-5,003,000 | $0 | $1,000,000 | $0 |
| Interest Income Non Operating | $2,150,000 | $437,000 | $363,000 | $213,000 |
| Operating Income | $-30,138,000 | $-18,602,000 | $-16,634,000 | $-29,343,000 |
| Net Income From Tax Loss Carryforward | - | - | - | $0 |
| Gross Profit | - | - | - | - |
| Per Share | ||||
| Diluted EPS | - | $-1.75 | $-6.50 | $-106.19 |
| Basic EPS | - | $-1.75 | $-6.50 | $-106.19 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-26,958,000 | $-17,039,000 | $-15,021,000 | $-27,750,000 |
| Total Unusual Items | $-5,003,000 | $0 | $1,000,000 | $-98,000 |
| Total Unusual Items Excluding Goodwill | $-5,003,000 | $0 | $1,000,000 | $-98,000 |
| Reconciled Depreciation | $1,030,000 | $1,126,000 | $1,250,000 | $1,380,000 |
| EBITDA (Bullshit earnings) | $-31,961,000 | $-17,039,000 | $-14,021,000 | $-27,848,000 |
| EBIT | $-32,991,000 | $-18,165,000 | $-15,271,000 | $-29,228,000 |
| Diluted NI Availto Com Stockholders | $-33,044,000 | $-18,377,000 | $-24,907,000 | $-65,010,000 |
| Impairment Of Capital Assets | $5,003,000 | $0 | - | - |
| Research And Development | $19,643,000 | $8,312,000 | $5,185,000 | $10,327,000 |
| Selling General And Administration | $10,595,000 | $10,690,000 | $11,674,000 | $19,016,000 |
| Other Gand A | $10,595,000 | $10,690,000 | $11,674,000 | $19,016,000 |
| Diluted Average Shares | - | $10,499,000 | $3,831,000 | $612,000 |
| Basic Average Shares | - | $10,499,000 | $3,831,000 | $612,000 |
| Gain On Sale Of Ppe | - | $0 | $1,000,000 | $0 |
| Minority Interests | - | - | - | $0 |
| Gain On Sale Of Security | - | - | - | $-98,000 |
| Preferred Stock Dividends | - | - | - | - |
| Other Special Charges | - | - | - | - |
Fetched: 2026-10-06
Balance Sheet (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $83,888,000 | $8,032,000 | $15,956,000 | $9,993,000 |
| Total Assets | $99,110,000 | $23,185,000 | $28,734,000 | $41,207,000 |
| Total Non Current Assets | $6,889,000 | $13,464,000 | $13,062,000 | $14,948,000 |
| Other Non Current Assets | $228,000 | $210,000 | $215,000 | $253,000 |
| Non Current Prepaid Assets | $83,000 | $26,000 | $26,000 | $50,000 |
| Non Current Note Receivables | $0 | $1,098,000 | $1,081,000 | $1,706,000 |
| Goodwill And Other Intangible Assets | $1,825,000 | $6,848,000 | $5,368,000 | $5,388,000 |
| Other Intangible Assets | $1,825,000 | $6,848,000 | $5,368,000 | $5,388,000 |
| Current Assets | $92,221,000 | $9,721,000 | $15,672,000 | $26,259,000 |
| Other Current Assets | $3,078,000 | $1,034,000 | $749,000 | $664,000 |
| Receivables | $1,104,000 | $105,000 | $713,000 | $204,000 |
| Notes Receivable | $1,104,000 | $0 | $713,000 | $0 |
| Accounts Receivable | $0 | $0 | - | $0 |
| Cash Cash Equivalents And Short Term Investments | $88,039,000 | $8,582,000 | $14,210,000 | $4,301,000 |
| Cash And Cash Equivalents | $56,395,000 | $8,582,000 | $14,210,000 | $4,301,000 |
| Other Receivables | - | $105,000 | - | $204,000 |
| Assets Held For Sale Current | - | - | $0 | $18,065,000 |
| Restricted Cash | - | - | $0 | $3,025,000 |
| Prepaid Assets | - | - | - | - |
| Inventory | - | - | - | - |
| Non Current Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $2,198,000 | $3,508,000 | $4,460,000 | $17,074,000 |
| Long Term Debt And Capital Lease Obligation | $1,652,000 | $2,199,000 | $3,507,000 | $3,476,000 |
| Current Debt And Capital Lease Obligation | $546,000 | $1,309,000 | $953,000 | $13,598,000 |
| Current Debt | - | $766,000 | $218,000 | $12,937,000 |
| Other Current Borrowings | - | $766,000 | $218,000 | - |
| Long Term Debt | - | - | $766,000 | - |
| Net Debt | - | - | - | $8,636,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $13,397,000 | $8,305,000 | $7,410,000 | $25,826,000 |
| Total Non Current Liabilities Net Minority Interest | $1,652,000 | $2,199,000 | $3,570,000 | $3,717,000 |
| Current Liabilities | $11,745,000 | $6,106,000 | $3,840,000 | $22,109,000 |
| Current Deferred Liabilities | $1,150,000 | $1,200,000 | $200,000 | $0 |
| Payables And Accrued Expenses | $8,700,000 | $2,721,000 | $1,119,000 | $2,691,000 |
| Payables | $4,423,000 | $2,252,000 | $659,000 | $2,277,000 |
| Accounts Payable | $4,423,000 | $2,188,000 | $358,000 | $1,849,000 |
| Tradeand Other Payables Non Current | - | $0 | $63,000 | $241,000 |
| Other Payable | - | $64,000 | $301,000 | $160,000 |
| Current Notes Payable | - | - | $0 | $12,937,000 |
| Interest Payable | - | - | $0 | $183,000 |
| Total Tax Payable | - | - | $0 | $268,000 |
| Liabilities Heldfor Sale Non Current | - | - | - | $0 |
| Other Current Liabilities | - | - | - | $1,941,000 |
| Equity | ||||
| Common Stock Equity | $85,713,000 | $14,880,000 | $21,324,000 | $15,381,000 |
| Total Equity Gross Minority Interest | $85,713,000 | $14,880,000 | $21,324,000 | $15,381,000 |
| Stockholders Equity | $85,713,000 | $14,880,000 | $21,324,000 | $15,381,000 |
| Gains Losses Not Affecting Retained Earnings | $-45,000 | $0 | - | $0 |
| Other Equity Adjustments | $-45,000 | - | - | - |
| Retained Earnings | $-365,268,000 | $-332,224,000 | $-313,847,000 | $-288,940,000 |
| Other | ||||
| Ordinary Shares Number | $55,698,561 | $19,349,201 | $8,623,676 | $1,015,503 |
| Share Issued | $55,698,561 | $19,349,201 | $8,623,676 | $1,015,503 |
| Tangible Book Value | $83,888,000 | $8,032,000 | $15,956,000 | $9,993,000 |
| Invested Capital | $85,713,000 | $15,646,000 | $22,308,000 | $28,318,000 |
| Working Capital | $80,476,000 | $3,615,000 | $11,832,000 | $4,150,000 |
| Capital Lease Obligations | $2,198,000 | $2,742,000 | $3,476,000 | $4,137,000 |
| Total Capitalization | $85,713,000 | $14,880,000 | $22,090,000 | $15,381,000 |
| Additional Paid In Capital | $450,970,000 | $347,085,000 | $335,162,000 | $304,320,000 |
| Capital Stock | $56,000 | $19,000 | $9,000 | $1,000 |
| Common Stock | $56,000 | $19,000 | $9,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,652,000 | $2,199,000 | $2,741,000 | $3,476,000 |
| Current Deferred Revenue | $1,150,000 | $1,200,000 | $200,000 | $0 |
| Current Capital Lease Obligation | $546,000 | $543,000 | $735,000 | $661,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,349,000 | $876,000 | $1,568,000 | $3,879,000 |
| Current Accrued Expenses | $4,277,000 | $469,000 | $460,000 | $414,000 |
| Net PPE | $4,753,000 | $5,282,000 | $6,372,000 | $7,551,000 |
| Accumulated Depreciation | $-2,053,000 | $-2,241,000 | $-1,486,000 | $-604,000 |
| Gross PPE | $6,806,000 | $7,523,000 | $7,858,000 | $8,155,000 |
| Construction In Progress | $24,000 | $0 | - | $0 |
| Other Properties | $1,667,000 | $2,865,000 | $3,215,000 | $3,536,000 |
| Machinery Furniture Equipment | $4,420,000 | $3,963,000 | $3,948,000 | $3,924,000 |
| Buildings And Improvements | $695,000 | $695,000 | $695,000 | $695,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $31,644,000 | $0 | - | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Non Current Accrued Expenses | - | - | - | $527,000 |
| Minority Interest | - | - | - | - |
| Work In Process | - | - | - | - |
| Raw Materials | - | - | - | - |
Fetched: 2026-10-06
Cash Flow Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-23,796,000 | $-15,320,000 | $-18,764,000 | $-36,174,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-23,218,000 | $-15,304,000 | $-18,554,000 | $-30,436,000 |
| Cash Flow From Continuing Operating Activities | $-23,218,000 | $-15,304,000 | $-18,554,000 | $-30,436,000 |
| Operating Gains Losses | - | - | $3,101,000 | $-680,000 |
| Investing Activities | ||||
| Capital Expenditure | $-578,000 | $-16,000 | $-210,000 | $-5,738,000 |
| Investing Cash Flow | $-31,999,000 | $742,000 | $906,000 | $7,009,000 |
| Cash Flow From Continuing Investing Activities | $-31,999,000 | $742,000 | $906,000 | $7,009,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,529,000 | $3,541,000 | $25,523,000 | $11,487,000 |
| Financing Cash Flow | $103,048,000 | $8,929,000 | $24,494,000 | $2,301,000 |
| Cash Flow From Continuing Financing Activities | $103,048,000 | $8,929,000 | $24,494,000 | $2,301,000 |
| Net Other Financing Charges | $-5,755,000 | $-294,000 | $116,000 | $-22,000 |
| Net Common Stock Issuance | $3,529,000 | $3,541,000 | $25,516,000 | $11,448,000 |
| Common Stock Issuance | $3,529,000 | $3,541,000 | $25,523,000 | $11,487,000 |
| Repurchase Of Capital Stock | - | $0 | $-7,000 | $-39,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-774,000 | $-695,000 | $-2,033,000 | $-9,625,000 |
| Issuance Of Debt | $15,290,000 | $0 | $895,000 | $500,000 |
| Interest Paid Supplemental Data | $72,000 | $212,000 | $749,000 | $687,000 |
| End Cash Position | $56,623,000 | $8,792,000 | $14,425,000 | $7,579,000 |
| Beginning Cash Position | $8,792,000 | $14,425,000 | $7,579,000 | $28,672,000 |
| Changes In Cash | $47,831,000 | $-5,633,000 | $6,846,000 | $-21,126,000 |
| Proceeds From Stock Option Exercised | $90,758,000 | $6,377,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $14,516,000 | $-695,000 | $-1,138,000 | $-9,125,000 |
| Net Long Term Debt Issuance | $14,516,000 | $-695,000 | $375,000 | $193,000 |
| Long Term Debt Payments | $-774,000 | $-695,000 | $-520,000 | $-307,000 |
| Long Term Debt Issuance | $15,290,000 | $0 | $895,000 | $500,000 |
| Interest Received Cfi | $75,000 | $758,000 | $0 | - |
| Net Investment Purchase And Sale | $-31,496,000 | $0 | $0 | $10,839,000 |
| Sale Of Investment | $10,800,000 | $0 | $0 | $10,839,000 |
| Purchase Of Investment | $-42,296,000 | $0 | - | $0 |
| Net PPE Purchase And Sale | $-578,000 | $-16,000 | $-94,000 | $-3,138,000 |
| Purchase Of PPE | $-578,000 | $-16,000 | $-210,000 | $-5,738,000 |
| Change In Working Capital | $2,522,000 | $479,000 | $-3,168,000 | $5,869,000 |
| Change In Other Working Capital | $-50,000 | $250,000 | $200,000 | $-100,000 |
| Change In Other Current Liabilities | $-490,000 | $-436,000 | $-389,000 | $-101,000 |
| Change In Payables And Accrued Expense | $5,337,000 | $1,073,000 | $-3,217,000 | $47,000 |
| Change In Accrued Expense | $3,114,000 | $-758,000 | $-1,726,000 | $672,000 |
| Change In Payable | $2,223,000 | $1,831,000 | $-1,491,000 | $-625,000 |
| Change In Account Payable | $2,223,000 | $1,831,000 | $-1,491,000 | $-625,000 |
| Change In Prepaid Assets | $-2,210,000 | $-408,000 | $238,000 | $938,000 |
| Change In Receivables | $-65,000 | $0 | $0 | $6,100,000 |
| Changes In Account Receivables | $-65,000 | $0 | $0 | $1,000,000 |
| Other Non Cash Items | $-80,000 | $-62,000 | $32,000 | $167,000 |
| Stock Based Compensation | $1,373,000 | $1,530,000 | $2,038,000 | $4,391,000 |
| Provisionand Write Offof Assets | $65,000 | $0 | $0 | $4,915,000 |
| Asset Impairment Charge | $5,110,000 | $0 | $3,100,000 | $18,465,000 |
| Amortization Of Securities | $-194,000 | $0 | $0 | $67,000 |
| Depreciation Amortization Depletion | $1,030,000 | $1,126,000 | $1,250,000 | $1,380,000 |
| Depreciation And Amortization | $1,030,000 | $1,126,000 | $1,250,000 | $1,380,000 |
| Amortization Cash Flow | $20,000 | $20,000 | $20,000 | $126,000 |
| Amortization Of Intangibles | $20,000 | $20,000 | $20,000 | $126,000 |
| Depreciation | $1,010,000 | $1,106,000 | $1,230,000 | $1,254,000 |
| Net Income From Continuing Operations | $-33,044,000 | $-18,377,000 | $-24,907,000 | $-65,010,000 |
| Common Stock Payments | - | $0 | $-7,000 | $-39,000 |
| Net Short Term Debt Issuance | - | $0 | $-1,513,000 | $-9,318,000 |
| Short Term Debt Payments | - | $0 | $-1,513,000 | $-9,318,000 |
| Net Intangibles Purchase And Sale | - | $0 | $1,000,000 | $0 |
| Sale Of Intangibles | - | $0 | $1,000,000 | $0 |
| Sale Of PPE | - | $0 | $116,000 | $2,600,000 |
| Gain Loss On Sale Of PPE | - | $0 | $3,909,000 | $-773,000 |
| Effect Of Exchange Rate Changes | - | - | $0 | $33,000 |
| Net Business Purchase And Sale | - | - | $0 | $-692,000 |
| Purchase Of Business | - | - | $0 | $-692,000 |
| Change In Inventory | - | - | $0 | $-1,015,000 |
| Purchase Of Intangibles | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | $98,000 |
Fetched: 2026-10-06